AVCRF Stock Chart & Stats
$0.02
$0.00(0.00%)
At close: 4:00 PM EDT
$0.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.02 - $0.08
Previous CloseN/A
Volume11.00
Average Volume (3M)60.67K
Market Cap
$3.97M
Enterprise Value$6.88
Total Cash (Recent Filing)$210.30K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding101,289,665
10 Day Avg. Volume71,961
30 Day Avg. Volume60,671
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)13.00
Price to Sales (P/S)9.49
P/FCF Ratio-5.60
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtEssentially no debt reduces fixed financing obligations and preserves flexibility to support operations or fund growth. Over the next several months this lowers bankruptcy risk and gives management more optionality when addressing cash burn or pursuing partnerships without interest burden.
Platform-driven Recurring RevenueThe HealthTab platform and in-pharmacy POCT programs create recurring, service-based revenue and stickiness with pharmacy partners. Structurally this supports scalable per-site economics and predictable revenue if pharmacy adoption and test volumes stabilize or grow over the coming months.
Historically Solid Gross MarginsA prior gross margin near 44% indicates the business can deliver attractive unit economics at scale. If volumes and pricing recover, gross-profit potential gives a durable path to margin recovery, helping leverage fixed costs and improving operating leverage over a multi-month horizon.
Bears Say
Steep Revenue DeclineA ~73% TTM revenue collapse undermines unit economics and scale-dependent margins, reducing ability to cover fixed costs. Over several months this heightens execution risk, signals market adoption or reimbursement issues, and makes recovery dependent on regaining site volumes.
Negative Operating And Free Cash FlowRecurrent negative operating and free cash flow increase reliance on external funding and raise dilution risk. Structurally, continued cash consumption limits investment in sales or platform improvement and pressures liquidity over the next several months absent clear cash-flow inflection.
Shrinking Equity Base / Dilution RiskA sharply reduced equity cushion leaves little buffer against continued losses and raises the probability of dilutive financings. Over a multi-month horizon this constrains strategic options and could force equity raises at unfavorable terms, impacting long-term shareholder value.
Avricore Health News
AVCRF FAQ
What was Avricore Health Inc.’s price range in the past 12 months?
Avricore Health Inc. lowest stock price was $0.01 and its highest was $0.08 in the past 12 months.
What is Avricore Health Inc.’s market cap?
Avricore Health Inc.’s market cap is $3.97M.
When is Avricore Health Inc.’s upcoming earnings report date?
Avricore Health Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 30 days.
How were Avricore Health Inc.’s earnings last quarter?
Currently, no data Available
Is Avricore Health Inc. overvalued?
According to Wall Street analysts Avricore Health Inc.’s price is currently Overvalued.
Does Avricore Health Inc. pay dividends?
Avricore Health Inc. does not currently pay dividends.
What is Avricore Health Inc.’s EPS estimate?
Avricore Health Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avricore Health Inc. have?
Avricore Health Inc. has 101,289,665 shares outstanding.
What happened to Avricore Health Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Avricore Health Inc.?
Currently, no hedge funds are holding shares in AVCRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avricore Health Inc.
Avricore Health Inc. operates within Canada, specializing in health data management and point-of-care technological solutions. Their primary offering is HealthTab, a precise, laboratory-quality diagnostic testing system designed for use in pharmacies. This enterprise maintains key alliances with prominent organizations such as Shoppers Drug Marts and Abbott. Established in 1996 and headquartered in Vancouver, Canada, the company previously operated as Vanc Pharmaceuticals Inc., adopting its current name, Avricore Health Inc., in October 2018.
Technical Analysis
BioMark Diagnostics
―
Telo Genomics Corp
―
StageZero Life Sciences Ltd
―
―
PanGenomic Health, Inc. Class A
―